margin expans rais pt
specialti segment repres sale margin
mrk shift specialti oncology/vaccines/anim segment
repres sale ebitda margin expand
benchmark segment highli accret keytruda/alli rev
vs street azn/eisai deal expect
rais vaccin gardasil estim front fda action label
expans adult yo open optim portfolio
divestitur women health/respiratori asset suitabl exit
reiter buy rais pt ep support
dcf
oncology/vaccines/ah growth drive om assumpt
transform specialty-focus busi root
primary-car benchmark mrk specialty-focus segment
roch oncolog glaxosmithklin vaccin zoeti anim
gaug margin associ busi leverag oncolog
vaccin anim health account total revenu
follow januvia franchis loe us/eu juli
ex-u januvia franchis sale mix shift primari
driver mrk ebitda margin expans mrk cfo note call
respons question gener believ your go
see oper margin expand move forward oncolog believ
street miss accret natur mrk keytruda collabor
allianc revenu astrazeneca azn-gb rate eisai
rate model mrk oncolog allianc revenu vs street
place upward pressur gross margin although
mileston commerci target amort blunt gm
impact out-year margin pressur post-januvia reiter
buy rais pt ep support dcf
clinical/regulatori risk commerci upside/downsid in-lin januvia life-
think posit deliv leverag ebitda margin
expand mrk oper
undergo materi transform view primari repres
tr target
sale invest behind global januvia diabet franchis vs
oncolog sale believ cut invest behind januvia reinvest
signific percentag behind build global oncolog commerci footprint
model assum oncolog repres mrk total sale primari shrink
oncolog grow bigger piec mrk top-lin think commercial/r footprint
becom focus support oper margin expans indic never
seen situat oncolog keytruda first time drug
cross mani differ tumor type mani indic result your deal need
promot sell multipl differ specialist infrastructur burden product like
keytruda probabl go see tradit oncolog compani given
although still benefici addit mrk bd invest azn/eisai add multipl
high-valu oncolog asset pipelin boost oper margin highli accret
allianc revenu expect mrk oncolog franchis achiev oper margin om low
vs roch rog-ch rate pharma divis oncolog
player major biopharma expect vaccin mrk top-lin vs
also assum mrk vaccin busi see om expans next five year
evidenc comment call look mix busi oncolog
vaccin rel would think tradit primari care infrastructur clearli
effici busi mrk anim health ah busi account revenu
model slight uptick think anim health franchis post
oper margin modestli anim health market leader zoeti
rate expect ah oper margin grow modestli next five year
next five year expect diabet oper margin flat januvia/janumet
sale margin pressur increas class competit think
manag appear warm idea share long-term outlook creation
sharehold valu street evidenc ceo comment earn call
think best way give long-term guidanc signific departur
tone call im go specif number im give long-term guidanc
model sales/ep cagr vs street
respiratori women health segment divest
remain commit anim health busi consid spin-off/sal unlik
pfizer hold spin buy plan ipo elanco see
postview note titl rais est solid global volum growth increas pt
manag encourag growth number post ah unit evid
comment point anim health busi grow quickli
industri peer anim health grow faster human health howev think
zero-in suitabl divestitur candid primari portfolio
busi drag top-lin growth corpor oper margin exampl primari
busi expect declin compound-annual-growth-rate declin busi unit
could choos divest declin busi non-cor conting abil
find will buyer
oncolog approach sale major om driver
oncolog franchis expect grow sale sale
made substanti invest build global oncolog busi expect oncolog keytruda
allianc revenu drive meaning oper margin expans out-year expect
oncolog achiev oper margin om keytruda alon account
mrk sale model one key sourc om expans keytruda
approv indic across differ tumor type us similar rang indic
ex-u mean mrk sale forc target sever oncolog specialist howev
given keytruda rapidli gain mindshar oncologist wall data quickli
becom standard-of-car variou tumor type think drive signific leverag
sg line vs spend sg preserv primari care asset market share like januvia
also invest materi line evidenc on-going keytruda clinic trial
howev would expect keytruda clinic footprint contract time brand matur
page
keytruda domin lung support io posit
establish leadership first-lin non-smal cell lung cancer nsclc highli
competit wall data keytruda shown overal surviv os benefit
myer buy opdivo us io market leader see note titl us io market mom
adj june opdivo/yervoy upsid lung cancer rapidli becom
major sourc keytruda us sale grow
hand bmi opdivo experienc revers trend opdivo us sale lung cancer declin
view mrk alreadi increas level keytruda
sale lung evid strong commerci success lung enhanc mrk
abil success launch upcom indic sourc keytruda us revenu
melanoma bladder cancer msi-high etc share new
non-squam nsclc patient alreadi get keytruda chemo regimen see
jump point sinc data present april remind
keytruda alimta chemo pdufa septemb squamou nsclc
set keytruda alreadi gain share becom standard care share sq
nsclc data pdufa set octob key upcom
regulatori mileston keytruda includ pdufa adjuv melanoma februari
keytruda launch lung set stage ex-u growth
intern keytruda sale driven melanoma lung lung cancer
largest indic major european market import note nsclc indic
yet launch eu market creat tailwind keytruda ex-
us revenu keytruda also receiv approv melanoma china although bmi opdivo
approv larger nsclc indic see note titl opdivo secur nsclc approv china
provinci price evolv provinci price io space expect evolv time
note latest io note recent see note azn imfinzi distant third io player
approv stage nsclc imfinzi also receiv posit eu chmp opinion stage
unresect nsclc indic set approval/launch tackl earli
stage nsclc competit threat studi keytruda multipl trial
 hoosier studi exhibit import near-term keytruda read-out exhibit includ
adjuvant/neoadjuv tnbc data
model keytruda sale vs street
mrk allianc revenu azn/eisai highli accret
anoth key aspect mrk expand oper margin see previou note titl eisai collabor
deal add anoth high-valu oncolog asset pipelin allianc revenu street
underappreci oncolog allianc revenu azn eisai view evidenc
consensu estim think mrk invest azn eisai respect
ad two high-valu oncolog asset multipl indic pipelin boost oper
margin highli accret allianc revenu azn/mrk lynparza lead parp drug
measur total/new prescript lynparza benefit robust growth ovarian indic
launch breast cancer indic note recent see note titl lynparza data
place upward pressur street allianc revenu posit result lynparza
ovarian cancer mainten add potenti broad indic mrk/azn plan initi
discuss global regul quickli possibl mrk/azn collabor chart
extens life-cycle program lynparza potenti launch us eu japan china
on-going phase trial exhibit selumetinib mek inhibitor collabor
asset mrk/azn partnership seen disappoint kra nsclc uveal melanoma
 differenti thyroid cancer think selumetinib could see better result combin
keytruda mrk collabor eisai focus oral tyrosin kinas inhibitor tki lenvima
approv second-lin renal cell carcinoma differenti thyroid cancer think lenvima
well-posit previou gener tki hold sutent inlyta
expect lenvima receiv approv second-lin hepatocellular carcinoma indic
on/befor august pdufa date eisai plan initi pivot combo studi
new indic six tumor type well basket trial near-term exhibit eisai bullish
commerci potenti lenvima project fy sale yoy
reach usd mrk/eisai show combin
keytruda lenvima demonstr impress object respons rate orr rcc
page
see note mrk attract econom innov asset support oncolog
allianc revenu significantli street
revis sales/ep street beat/rais
model sales/ep vs street rais sale
yoy vs street driven higher keytruda gardasil
diabet partial off-set lower zostavax sale gross margin
slightli street model sm a/r expens vs street
lower tax rate prior vs street higher sale lower
tax off-set higher d/cog exp result ep unchang vs street
page
exhibit keytruda access first-lin lung cancer market
page
exhibit keytruda clinic develop lung cancer
page
exhibit mrk clinic data readout regulatori catalyst next
note mrk/azn lynparza achiev posit result studi keytruda receiv approv cervic cancer pmbcl
page
note potenti number launch us eu japan china on-going phase trial vascular endotheli growth factor receptor
page
page
lower yoy
fx
page
ema approv expect keytruda alimta chemo nsclc base data
fda approv expect keytruda alimta chemo nsclc base data
pdufa gardasil women men age prioriti review
pdufa doravirin nda combo antiretrovir
pdufa keytruda chemo carbo paclitaxel/nab squamou nsclc prioriti review base
primari complet apec studi patient prodrom alzheim diseas primari complet april
pdufa keytruda previous treat hepatocellular carcinoma base data prioriti review
data expect mono/combo tnbc chl
pdufa keytruda recurrent/metastat head neck cancer
data expect gastric mono/combo nmibc bladder
pdufa keytruda adjuv melanoma base
readout polo trial pancreat cancer ovarian cancer lynparza cediranib vegfr combo
data expect bladder mono/combo
data expect rcc combo
tnbc keytruda chemo studi
page
materi product
materi product
page
exhibit estim strh vs consensu us million expect ep
page
page
page
page
materi product
depreci
equival
prepaid expens tax
net properti plant equip
loan payabl current portion lt debt
defer incom tax non-current liabil
accumul comprehens incom
total sharehold equiti liabil
page
exhibit statement flow
depreci amort
chang work capit
oper
purchas secur invest
sale secur invest
proce sale busi
acquisit busi
invest
chang short-term debt
proce issuanc lt debt
payment long term debt
purchas treasuri stock
proce stock option
financ
effect exchang rate
cash/equival begin period
cash/equival end period
page
merck co inc commit premier research-intens biopharmaceut
compani strategi discov develop provid innov product servic save
improv live around world innov medicin vaccin anim health product
gener us ex-u total revenu merck core area
focu oncolog diabet virolog vaccin account
sale respect sever key brand product oncolog keytruda diabet januvia/janumet/
marizev japan vaccin gardasil drive growth addit growth opportun
immunolog women hospital/acut along grow biosimilar portfolio mrk
anim busi yield sale repres total sale
rate buy key global leader immuno-oncolog io market flagship
asset keytruda establish foundat io asset approv favor clinic data
multipl tumor type keytruda earlier expect posit result non-smal cell lung cancer
nsclc sourc upsid allow maintain first-mov advantag import
think one broadest clinic trial program
trial tumor type along combin trial sinc septemb keytruda
approv key indic us also grant number
breakthrough therapi design keytruda domin io market wall-of-data
extend mrk collabor astrazeneca lynparza parp deal
diabet mrk januvia/janumet franchis pressur type diabet market move
away toward newer effect agent like growth
mrk diabet franchis expect come inhibitor steglatro ertugliflozin
weekli marizev launch japan insulin conjug expect
launch
outsid oncolog anim health continu show strong growth think mrk
franchis consider competit pressur signific pressur come
virolog busi also see modest downward pressur mrk vaccin busi
zostavax face competit glaxosmithklin shingrix gardasil expect declin
us/eu due adopt two dose regimen vs previou three dose
model sales/ep cagr vs street
valuat risk
target price assum merck trade ep estim support
discount cash flow dcf model multipl ep group averag
think appropri given mrk leadership immuno-oncolog space
keytruda first-mov advantag nsclc
risk rate target price includ failur capit truda first-mov advantag
nsclc approv use januvia franchis see materi declin sale due rise
competit oral dpp-iv segment clinic regulatori risk keytruda
relebactam infect herp zoster valent pneumococc vaccin
global price risk invest risk relat biopharmaceut industri includ global price risk
payer polit risk clinic develop risk regulatori risk commerci risk legal
risk patent challeng
page
compani mention note
compani buy john bori
astrazeneca plc azn-gb rate
eisai co ltd rate
glaxosmithklin plc gsk rate
roch hold ltd genusssch rog-ch rate
zoeti inc class rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
